App combining genomics, fitness and diet highlights nutrigenomics trend
Genetic testing businesses to personalize fitness and diet regimens are making their way into the consumer space, for better or for worse.
These are the key players in the home health testing market
The report lists obvious choices like Quest Diagnostics, LabCorp and 23andMe - and deigns to include even Theranos, despite its recent spate of bad PR.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening?
Who are some other players in the cancer liquid biopsy market? We've got Trovagene, Circulogene, Pathway Genomics and more... but can they compete with Illumina's new startup, Grail?
Pathway Genomics latest app combines cognitive computing, genetics and personal wellness
In an example of the kind of messages users would get, the app may direct them to avoid certain foods based on their metabolism.
Pathway Genomics pays more than $4M to settle kickback allegations from DOJ
"While genomic testing is a valuable and relatively recent medical tool, when specialized laboratories pay for referrals they aren't breaking any new ground but rather engaging in the same old kickback schemes," Special Agent Chris Schrankof said in a statement.
Circulogene launches new liquid biopsy test for cancer
Alabama startup CirculoGene Theranostics has released a new liquid biopsy test for cancer monitoring - but will it stick?
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Other diagnostic companies utilize regulatory loopholes, not just Theranos
Several diagnostic companies use the "laboratory developed test" loophole to avoid regulation and market tests without FDA approval, for better or worse.
Pathway Genomics responds to FDA’s concerns on liquid biopsy test
Pathway Genomics has responded to FDA's warning letter that its liquid biopsy test isn't sufficiently validated clinically, and has an inappropriate marketing model.
Pathway Genomics gets FDA warning letter for its liquid biopsy test
The FDA just sent Pathway Genomics a warning letter for its new liquid biopsy test, calling it "a high risk test that has not received adequate clinical validation and may harm the public health."
Pathway Genomics launches first liquid biopsy test for cancer
Pathway Genomics just launched a liquid biopsy test for multiple cancers, meant for disease monitoring or screening in high-risk patients. It has important implications in precision medicine.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
From a heart patient’s use of the Apple Watch to Pathway Genomics’ app: 5 must-read stories from MedCity News this week
Here's a look at some of the most popular stories from this past week in healthcare.
Pathway Genomics unveils app to order genetic test to determine optimum fitness, diet regimen
The Pathway Fit app analyzes more than 75 genetic markers known to impact metabolism, exercise, and energy consumption within our bodies.
Study: Customers of commercial genomic testing services understand results more than expected
For average people without a science or healthcare background, genetic testing results would seemingly be difficult to understand, but that might not be the case.
Morning Read: Signs of life in the biotech exit market?
Highlights of the important and the interesting from the world of healthcare: Signs of life in the biotech exit market? Well, maybe. Fourteen venture-backed companies have filed IPOs this year, compared with eight all of last year and seven in 2008. Three of those have been biotechs–Aveo, Alimera and Ironwood. Still, that’s not enough to […]